ML22095A285

627275-Amendment 24 License 50-23214-01/030-20372 for Diagnostic Health Center of Anchorage, LLC

ML22095A285
Person / Time
Site:	03020372
Issue date:	04/05/2022
From:	Latischa Hanson Division of Nuclear Materials Safety IV
To:	Document Control Desk
References
License-627275-165144
Download: ML22095A285 (1)

See also: IR 05000232/2014001

Text

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

NRC FORM 374

PAGE

OF

1

3

Amendment No. 24

PAGES

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I,

Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued

authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s)

and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This

license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and

orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

Anchorage, AK 99508

2. 4100 Lake Otis Parkway #102

A wholly owned subsidiary of Alliance HealthCare

Services

1. Diagnostic Health Center of Anchorage, LLC

4. Expiration Date: March 31, 2025

Docket No.:

5.

030-20372

License No.: 50-23214-01 is

amended in its entirety to read as

follows:

Reference No.:

3.

In accordance with letter dated

July 6, 2021

6.

7.

8.

Byproduct, source,

and/or special nuclear

material

Chemical and/or physical form

Maximum amount that licensee

may possess at any one time

under this license

9.

Authorized use

A.

A.

A.

A.

For use in uptake, dilution and

excretion studies permitted by 10 CFR

35.100.

Any

As Needed

Any byproduct material

permitted by 10 CFR 35.100

B.

B.

B.

B.

For use in imaging and localization

studies permitted by 10 CFR 35.200.

Any

As Needed

Any byproduct material

permitted by 10 CFR 35.200

C.

C.

C.

C.

Any sodium iodide Iodine-131 use

permitted by 10 CFR 35.300 for which

the patient can be released under the

provisions of 10 CFR 35.75.

Any

500 millicuries total

Iodine-131

D.

D.

D.

D.

For use in in-vitro studies.

Prepackaged Kits

50 millicuries total

Any byproduct material

permitted by 10 CFR 31.11

License No.:

Docket or Reference No.:

U.S. NUCLEAR REGULATORY COMMISSION

NRC FORM 374A

MATERIALS LICENSE

SUPPLEMENTARY SHEET

PAGES

OF

PAGE

3

2

50-23214-01

030-20372

Amendment No. 24

CONDITIONS

10. Licensed material may be used only at the licensees facilities located at Lake Otis Medical Plaza, 4100 Lake Otis Parkway #102,

Anchorage, Alaska.

11.

The Radiation Safety Officer for this license is Kay Kassel, MS, CNMT.

12. Licensed material shall only be used by, or under the supervision of:

A.

Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B.

The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Material and Use

Marc R. Beck, M.D.

35.100; 35.200; Oral administration of sodium iodide I-131; 31.11

Robert L. Bridges, M.D.

35.100; 35.200; Oral administration of sodium iodide I-131; 31.11

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the

minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

License No.:

Docket or Reference No.:

U.S. NUCLEAR REGULATORY COMMISSION

NRC FORM 374A

MATERIALS LICENSE

SUPPLEMENTARY SHEET

PAGES

OF

PAGE

3

3

50-23214-01

030-20372

Amendment No. 24

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements,

representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to

those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the

licensees ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory

Commissions regulations shall govern unless the statements, representations, and procedures in the licensees application and

correspondence are more restrictive than the regulations.

A. Application dated October 20, 2014 (ML14336A723)

B. Letter dated February 16, 2015 with enclosures (ML15061A178)

C. Letter dated July 6, 2021 (ML21196A052)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By:

Date:

Latischa M. Hanson

Region IV

ML22073A267

April 5, 2022

Latischa M. Hanson

Digitally signed by Latischa M.

Hanson

Date: 2022.04.05 19:20:39 -05'00'